Retention of immunogenicity produced by mucin1 peptides with glycosylation site substitutions

Immunopharmacology and Immunotoxicology

Volumn 32, Issue 4, 2010, Pages 647-655

  Wright, Stephen E ^a,b,c   Quinlin, Imelda S ^a,b,c   Rewers Felkins, Kathleen A ^a,b,c   Dombrowski, Ken E ^a,b,d,e   Phillips, Catherine A ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c Harrington Cancer Center   (United States)

^d ATLANTA VA MEDICAL CENTER   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CTL; Glycosylation site; Immunogenicity; MUC1; Substitutions

Indexed keywords

ASPARAGINE; MUCIN 1; SERINE; TYROSINE;

ARTICLE; BREAST ADENOCARCINOMA; CANCER STAGING; CYTOTOXIC T LYMPHOCYTE; GLYCOSYLATION; HUMAN; HUMAN CELL; IMMUNOGENICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SUBSTITUTION REACTION; TANDEM REPEAT;

AMINO ACID SUBSTITUTION; BREAST NEOPLASMS; CELL LINE, TUMOR; CYTOKINES; CYTOTOXICITY TESTS, IMMUNOLOGIC; CYTOTOXICITY, IMMUNOLOGIC; FEMALE; GLYCOSYLATION; HIV ENVELOPE PROTEIN GP120; HUMANS; INTERLEUKIN-2; KILLER CELLS, LYMPHOKINE-ACTIVATED; KILLER CELLS, NATURAL; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MINISATELLITE REPEATS; MUCIN-1; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 78149249609     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.3109/08923971003671082     Document Type: Article

References (37)

1. Greenberg, P.D., Riddell, S.R. Tumor-specific T-cell immunity: ready for prime time? J. Natl. Cancer Inst. 1992; 84: 1059-1061.
2. Rosenberg, S.A. Immunotherapy and gene therapy of cancer. Cancer Res. 1991; 51: 5074s-5079s.
3. Urban, J.L., Schreiber, H. Tumor antigens. Annu. Rev. Immunol. 1992; 10: 617-644.
4. Gendler, S.J. MUC1, the renaissance molecule. J. Mammary Gland Biol. Neoplasia 2001; 6: 339-353.
5. Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., Burchell, LA highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats. J. Biol. Chem. 1988; 263:12820-12823.
6. Lan, M.S., Batra, S.K., Qi, W.N., Metzgar, R.S., Hollingsworth, M.A. Cloning and sequencing of a human pancreatic tumor mucin cDNA. J. Biol. Chem. 1990; 265: 15294-15299.
7. Hanisch, F.G., Uhlenbruck, G., Peter-Katalinic, J., Egge, H., Dabrowski, J., Dabrowski, U. Structures of neutral O-linked polylactosaminoglycans on human skim milk mucins. A novel type of linearly extended poly-N-acetyllactosamine backbones with Gal beta(l-4)GlcNAc beta(l-6) repeating units. J. Biol. Chem. 1989; 264: 872-883.
8. Guevara-Patiño, J.A., Engelhorn, M.E., Turk, M.J., Liu, C., Duan, F., Rizzuto, G., Cohen, A.D., Merghoub, T., Wolchok, J.D., Houghton, A.N. Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. J. Clin. Invest. 2006; 116: 1382-1390.
9. Burchell, J., Gendler, S., Taylor-Papadimitriou, J., Girling, A., Lewis, A., Millis, R., Lamport, D. Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin. Cancer Res. 1987; 47: 5476-5482.
10. Linsley, P.S., Brown, J.P., Magnani, J.L., Horn, D. Monoclonal antibodies reactive with mucin glycoproteins found in sera from breast cancer patients. Cancer Res. 1988; 48: 2138-2148.
11. Perey, L., Hayes, D.F., Maimonis, P., Abe, M., O'Hara, C., Kufe, D.W. Tumor selective reactivity of a monoclonal antibody prepared against a recombinant peptide derived from the DF3 human breast carcinoma-associated antigen. Cancer Res. 1992; 52:2563-2568.
12. Nishimori, I., Johnson, N.R., Sanderson, S.D., Perini, F., Mountjoy, K., Cerny, R.L., Gross, M.L., Hollingsworth, M.A. Influence of acceptor substrate primary amino acid sequence on the activity of human UDP-N-acetylgalactosamine: polypeptide N-acetylgalactosaminyltransferase. Studies with the MUC1 tandem repeat. J. Biol. Chem. 1994; 269: 16123-16130.
13. Barnd, D.L., Lan, M.S., Metzgar, R.S., Finn, O.J. Specific, major histocompatibility complex-unrestricted recognition of tumor-associated mucins by human cytotoxic T cells. Proc. Natl. Acad. Sci. USA. 1989; 86: 7159-7163.
14. Ioannides, C.G., Fisk, B., Jerome, K.R., Irimura, T., Wharton, J.T., Finn, O.J. Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. J. Immunol. 1993; 151: 3693-3703.
15. Jerome, K.R., Barnd, D.L., Bendt, K.M., Boyer, C.M., Taylor- Papadimitriou, J., McKenzie, I.F., Bast, R.C. Jr Finn, O.J. Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. Cancer Res. 1991; 51: 2908-2916.
16. Orr, M.K., Burnside, J.S., Phillips, C.A., Philip, R., Dombrowski, K.E., Wright, S.E. MHC-restricted presentation of a single repeat of MUC1 mucin. Immunol. Invest. 2007; 36: 271-283.
17. Wright, S.E., Kilinski, L., Talib, S., Lowe, K.E., Burnside, J.S., Wu, J.Y., Dolby, N., Dombrowski, K.E., Lebkowski, J.S., Philip, R. Cytotoxic T lymphocytes from humans with adenocarcinomas stimulated by native MUC1 mucin and a mucin peptide mutated at a glycosylation site. J. Immunother. 2000; 23: 2-10.
18. Wright, S.E., Rewers-Felkins, K.A., Quinlin, I.S., Fogler, W.E., Phillips, C.A., Townsend, M., Robinson, W., Philip, R. MHC-unrestricted lysis of MUC1-expressing cells by human peripheral blood mononuclear cells. Immunol. Invest. 2008; 37: 215-225.
19. Sugiura, D., Aida, S., Denda-Nagai, K., Takeda, K., Kamata-Sakurai, M., Yagita, H., Irimura, T. Differential effector mechanisms induced by vaccination with MUC1 DNA in the rejection of colon carcinoma growth at orthotopic sites and metastases. Cancer Sci. 2008; 99: 2477-2484.
20. Rong, Y., Jin, D., Wu, W., Lou, W., Wang, D., Kuang, T., Ni, X., Qin, X. Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 2009; 9:191.
21. Shi, F.F., Gunn, G.R., Snyder, L.A., Goletz, T.J. Intradermal vaccination of MUC1 transgenic mice with MUC1/IL-18 plasmid DNA suppresses experimental pulmonary metastases. Vaccine. 2007; 25: 3338-3346. Epub 2007 Jan 22.
22. Tang, C.K., Sheng, K.C., Pouniotis, D., Esparon, S., Son, H.Y., Kim, C.W.; Pietersz, G.A., Apostolopoulos, V. Oxidized and reduced mannan mediated MUC1 DNA immunization induce effective anti-tumor responses. Vaccine. 2008; 26: 3827-3834.
23. Westerlind, U., Hobel, A., Gaidzik, N., Schmitt, E., Kunz, H. Synthetic vaccines consisting of tumor-associated MUC1 glycopeptide antigens and a T-cell epitope for the induction of a highly specific humoral immune response. Angew. Chem. Int. Ed. Engl. 2008; 47: 7551-7556.
24. Watson, J.D., Hopkins, N.H., Roierts, J.W., Steitz, J.A., Weiner, J.D. Distinction between regular and irregular polymers. In Watson, J. D., Hopkins, N. H., Roierts, J. W., Steitz, J. A., Weiner, J. D., eds. Molecular Biology of the Gene, 4th ed. (pp. 42-44). Menlo Park, CA: The Benjamin/Cummings Publishing Company, Inc, 1988.
25. Hopp, T.P., Woods, K.R. Prediction of protein antigenic determinants from amino acid sequences. Proc. Natl. Acad. Sci. USA. 1981; 78: 3824-3828.
26. Kyte, J., Doolittle, R.F. A simple method for displaying the hydropathic character of a protein. J. Mol. Biol. 1982; 157:105-132.
27. Ho, D.D., Kaplan, J.C., Rackauskas, I.E., Gurney, M.E. Second conserved domain of gp 120 is important for HIV infectivity and antibody neutralization. Science 1988; 239:1021-1023.
28. Wright, S.E., Khaznadar, R., Wang, Z., Quinlin, I.S., Rewers-Felkins, K.A., Phillips, C.A., Patel, S. Generation of MUC1-stimulated mononuclear cells using optimized conditions. Scand. J. Immunol. 2008; 67: 24-29.
29. Kornbluth, J., Flomenberg, N., Dupont, B. Cell surface phenotype of a cloned line of human natural killer cells. J. Immunol. 1982; 129:2831-2837.
30. Roehm, N.W., Rodgers, G.H., Hatfield, S.M., Glasebrook, A.L. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. J. Immunol. Methods 1991; 142: 257-265.
31. Jost, L.M., Kirkwood, J.M., Whiteside, T.L. Improved short - and long-term XTT-based colorimetric cellular cytotoxicity assay for melanoma and other tumor cells. J. Immunol. Methods 1992; 147: 153-165.
32. Ahmed, S.A., Gogal, R.M. Jr, Walsh, J.E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay. J. Immunol. Methods 1994; 170: 211-224.
33. Quinlin, I.S., Burnside, J.S., Dombrowski, K.E., Phillips, C.A., Dolby, N., Wright, S.E. Context of MUC1 epitope: immunogenic-ity. Oncol. Rep. 2007; 17: 453-456.
34. Wajchman, H.J., Pierce, C.W., Varma, V.A., Issa, M.M., Petros, J., Dombrowski, K.E. Ex vivo expansion of CD8+CD56+ and CD8+CD56 - natural killer T cells specific for MUC1 mucin. Cancer Res. 2004; 64:1171-1180.
35. Hernandez, J., Garcia-Pons, F., Lone, Y.C., Firat, H., Schmidt, J.D., Langlade-Demoyen, P., Zanetti, M. Identification of a human telomerase reverse transcriptase peptide of low affinity for HLA A2.1 that induces cytotoxic T lymphocytes and mediates lysis of tumor cells. Proc. Natl. Acad. Sci. USA. 2002; 99:12275-12280.
36. Dionne, S.O., Myers, C.E., Smith, M.H., Lake, D.F. Her-2/neu altered peptide ligand-induced CTL responses: implications for peptides with increased HLA affinity and T-cell-receptor interaction. Cancer Immunol. Immunother. 2004; 53: 307-314.
37. Pisarev, V.M., Kinarsky, L., Caffrey, T., Hanisch, F.G., Sanderson, S., Hollingsworth, M.A., Sherman, S. T cells recognize PD(N/T) R motif common in a variable number of tandem repeat and degenerate repeat sequences of MUC1. Int. Immunopharmacol. 2005;5:315-330.